OVERVIEW

Peptide Therapeutics

Protagonist Therapeutics is a clinical-stage biopharmaceutical company with multiple peptide-based new chemical entities in different stages of development. Discovered through our proprietary technology platform, our differentiated assets are designed to impact key biological targets and pathways, providing the potential to add new indications, and expanding our pipeline efficiently including orphan and large-market opportunities that address areas where there is significant unmet medical need. Currently, we have five novel peptidic assets, PTG-300, PTG-200, PN-232, PN-235, and PN-943 in clinical development.

Management

Dinesh V. Patel, Ph.D.

Dinesh V. Patel, Ph.D.

President & CEO Bio Bio
X
Dinesh V. Patel, Ph.D.

Dinesh V. Patel, Ph.D.

Director,
President & CEO, Protagonist Therapeutics

Dr. Patel has served as a member of the board of directors and as the President and Chief Executive Officer of Protagonist since December 2008. He has 33 years of executive, entrepreneurial, and scientific experience that span the pharmaceutical, biotechnology and biopharmaceutical industries. Prior to joining Protagonist Therapeutics, Dr. Patel served from 2006 to 2008 as the President and Chief Executive Officer of Arête Therapeutics, a privately held company focused on novel drugs for metabolic syndrome. Previously, he was the Chief Executive Officer and Co-founder of Miikana Therapeutics, an oncology based company, from 2003 until acquired by Entremed (later renamed CASI Pharmaceuticals) in 2005. Prior to Miikana, Dr. Patel held positions of increasing responsibility at Versicor (later renamed Vicuron) from 1996 to 2003, most recently as Senior Vice President of Drug Discovery and Licensing. Vicuron research and development efforts led to two marketed drugs, anidulafungin (Eraxis®), and Dalbavancin (Dalvance®), and the Company was acquired by Pfizer in 2005 in a $1.9 billion cash transaction. From 1993 to 1996, Dr. Patel was a director of chemistry at the combinatorial chemistry company Affymax. Dr. Patel was a medicinal chemist at Bristol-Myers Squibb from 1985 to 1993. Dr. Patel received his Ph.D. in Chemistry from Rutgers University, New Jersey and his B.S. in Industrial Chemistry from S. P. University, Vallabh Vidyanagar, India.

David Y. Liu, Ph.D.

David Y. Liu, Ph.D.

Chief Scientific Officer,
Head of Discovery & Pre-Clinical Development
Bio Bio
X
David Y. Liu, Ph.D.

David Y. Liu, Ph.D.

Chief Scientific Officer,
Head of Discovery & Pre-Clinical Development

Dr. Liu has served as our Chief Scientific Officer (CSO) since May 2013 and has served as CSO and Head of Research and Development since February 2016. Prior to Protagonist Therapeutics, Dr. Liu was the Chief Operating Officer and a co-founder of Trenovus, Inc., from 2010 to 2012. Prior to Trenovus, Dr. Liu was Vice President of Research at FibroGen Inc., from 2002 to 2010. Prior to Fibrogen, Dr. Liu served as Director of Inflammation Research at Scios, Inc., now part of Johnson & Johnson, from 1992 to 2002. Dr. Liu held a position as an academic researcher at Brigham and Women’s Hospital, Harvard Medical School, and was Instructor and Assistant Professor in the Department of Medicine, Harvard Medical School, from 1976 to 1986. Dr. Liu received his Ph.D. in microbiology and immunology from Michigan State University, and his B.S. in chemistry from The University of Chicago.

Samuel Saks, M.D.

Samuel Saks, M.D.

Clinical Development Advisor Bio Bio
X
Samuel Saks, M.D.

Samuel Saks, M.D.

Clinical Development Advisor

Dr. Saks serves as our Clinical Development Advisor. His leadership in drug development spans decades. Prior to his work with Protagonist, Dr. Saks served as Chief Development Officer and board member at Auspex Pharmaceuticals until the time of its acquisition by Teva Pharmaceuticals. Before his tenure at Auspex, Dr. Saks was a co-founder of Jazz Pharmaceuticals where he also served as Chief Executive Officer. Earlier in his career, Dr. Saks held positions as company group chairman of ALZA Corporation and member of the Johnson & Johnson Pharmaceutical Operating Committee. Dr. Saks has also held leadership and management positions at Schering-Plough, Xoma and Genentech. Dr. Saks serves on the boards of directors of Quanta Therapeutics and Hinge Bio. Dr. Saks received a B.S. in Biology and his M.D. from the University of Illinois.

Suneel Gupta, Ph.D.

Suneel Gupta, Ph.D.

Chief Development Officer Bio Bio
X
Suneel Gupta, Ph.D.

Suneel Gupta, Ph.D.

Chief Development Officer

Dr. Gupta joined as Chief Development Officer in Jan 2019. Dr. Gupta serves on the scientific advisory boards of several pharmaceutical companies. Prior to joining Protagonist, he was Chief Scientific Officer (CSO) of Impax Pharmaceuticals from 2008 to 2019. Prior to Impax, he was Senior Vice President (SVP) and Distinguished Research Fellow at Johnson & Johnson, where he led the early development from 2002-2008. Prior to J&J, he was at ALZA from 1989-2001, where he had increasing levels of responsibility until promoted to Vice President of Clinical Pharmacology & Product Discovery. Dr. Gupta received his PhD in Pharmacokinetics from the University of Manchester, UK in 1987 and did a postdoctoral fellowship in Clinical Pharmacology at the University of California, San Francisco.

Paula O’Connor, M.D

Paula O’Connor, M.D

Senior Vice President,
Clinical Development
X
Paula O’Connor, M.D

Paula O’Connor, M.D

Senior Vice President,
Clinical Development
Don Kalkofen

Don Kalkofen

Chief Financial Officer Bio Bio
X
Don Kalkofen

Don Kalkofen

Chief Financial Officer

Prior to joining the Protagonist Therapeutics team, Mr. Kalkofen served in an advisory role as Senior Advisor, Finance, to the Company. Mr. Kalkofen’s experience includes over fifteen years as a Chief Financial Officer in both public and private companies. Mr. Kalkofen has had an extensive consulting career and held positions including the Chief Financial Officer at App Annie; Assistant Controller at Align Technology; Vice President of Finance at Simplifier Corporation and Chief Financial Officer of Innovative Bank. Earlier in his career, Mr. Kalkofen served as the Chief Financial Officer for West Coast Bancorp, Pinnacle Bank and DecisionPoint Applications. He started his career at PricewaterhouseCoopers, received his B.A. in accounting from Washington State University, and is a Certified Public Accountant and Certified Global Management Accountant.

Tracy Woody

Tracy Woody

Executive Vice President,
Commercial Strategy
Bio Bio
X
Tracy Woody

Tracy Woody

Executive Vice President,
Commercial Strategy

Ms. Woody has over 20 years of experience in pharmaceuticals, biologics, and medical devices. Prior to joining Protagonist Therapeutics, Ms. Woody served as the Chief Commercial Officer at Versartis and KemPharm Inc. Earlier in her career, Ms. Woody served as Vice President of Sales and Marketing at NextWave Pharmaceuticals, and Vice President of Business Development at Greer Laboratories. Ms. Woody has been an advisor to emerging biotech companies in diverse areas such as product launch, corporate development and commercial opportunity assessment. Ms. Woody serves on the board of Esperion Therapeutics. Ms. Woody holds a B.S. in Health Promotion and Applied Physiology from East Carolina University.

Matthew Gosling

Matthew Gosling

Executive Vice President,
General Counsel
Bio Bio
X
Matthew Gosling

Matthew Gosling

Executive Vice President,
General Counsel

Mr. Gosling joined Protagonist as Executive Vice President, General Counsel in September 2020. He has more than 20 years of legal expertise advising Bay Area life sciences and pharmaceutical companies. Prior to Protagonist, Mr. Gosling served as General Counsel of Depomed, a commercial stage specialty pharmaceutical company, for 12 years. Prior to Depomed, he was a partner in the global law firm of Heller Ehrman, where his practice focused on general corporate, securities, M&A and collaboration matters for public life science companies. Mr. Gosling holds a J.D. from the University of Chicago and a B.S. in Economics from Trinity University in San Antonio, Texas.

Mohammad Masjedizadeh

Mohammad Masjedizadeh

Executive Vice President,
Chief Technical Officer
X
Mohammad Masjedizadeh

Mohammad Masjedizadeh

Executive Vice President,
Chief Technical Officer
Larry Mattheakis

Larry Mattheakis

Senior Vice President,
Discovery Biology & Translational Research
X
Larry Mattheakis

Larry Mattheakis

Senior Vice President,
Discovery Biology & Translational Research
Ashok Bhandari

Ashok Bhandari

Senior Vice President,
Discovery Chemistry & Process Research
X
Ashok Bhandari

Ashok Bhandari

Senior Vice President,
Discovery Chemistry & Process Research
Carter King

Carter King

Senior Vice President,
Business Development
X
Carter King

Carter King

Senior Vice President,
Business Development

Mr. King joined Protagonist Therapeutics as Vice President of Business Development in September 2018. Prior to Protagonist Therapeutics, he was a Business Development Consultant for Achaogen, Inc. from 2016 to 2018. Previously, Mr. King was Vice President of Finance and Corporate Development at Omniox, Inc from 2015 to 2016, and held several management roles, including Vice President of Corporate Development for AcelRx Pharmaceuticals from 2006 to 2015. Earlier in his career, Mr. King worked in corporate development and finance at ALZA Corporation and Coulter Pharmaceutical. He received an M.B.A. with honors from Columbia Business School and a B.A. in Business Economics from U.C., Santa Barbara.

Abha Bommireddi

Abha Bommireddi

Senior Vice President,
Program Management
X
Abha Bommireddi

Abha Bommireddi

Senior Vice President,
Program Management
Mark Smythe, Ph.D.

Mark Smythe, Ph.D.

Founder & Vice President,
Technology
X
Mark Smythe, Ph.D.

Mark Smythe, Ph.D.

Founder & Vice President,
Technology

Dr. Smythe is the founder of Protagonist Therapeutics and has served as our Vice President of Technology since 2013, having previously served as our Chief Scientific Officer from 2009 to 2010 and our Chief Executive Officer from 2001 to 2009. He has extensive experience in industry-based research management and technology commercialization. Prior to Protagonist Therapeutics, he was Principal Investigator at the Centre for Drug Design and Development, now the Institute for Molecular Bioscience in Brisbane, Australia, from 1994 to 2001. Dr. Smythe earned a Ph.D. in Medicinal Chemistry from Melbourne University and a B.Sc (Hons) in Synthetic Organic Chemistry from James Cook University.

Carena Spivey

Carena Spivey

Executive Director,
Human Resources
X
Carena Spivey

Carena Spivey

Executive Director,
Human Resources

Board of Directors

Harold E. “Barry” Selick, Ph.D.

Harold E. “Barry” Selick, Ph.D.

Chairman, Independent Director, Vice Chancellor for Business Development, Innovation and Partnerships, UCSF Bio Bio
X
Harold E. “Barry” Selick, Ph.D.

Harold E. “Barry” Selick, Ph.D.

Chairman, Independent Director,
Vice Chancellor for Business Development, Innovation and Partnerships at University of California, San Francisco

Dr. Selick has served on our board of directors since February 2009. Dr. Selick is Vice Chancellor for Business Development, Innovation and Partnerships at University of California San Francisco. He also serves as Chairman of Molecular Templates effective August 2017. He served as CEO of Threshold Pharmaceuticals from June 2002 to April 2017, which recently merged with Molecular Templates. From June 2002 until July 2007, Dr. Selick was also a Venture Partner of Sofinnova Ventures, Inc., a venture capital firm. From January 1999 to April 2002, he was Chief Executive Officer of Camitro Corporation, a biotechnology company. From 1992 to 1999, he was at Affymax Research Institute, the drug discovery technology development center for Glaxo Wellcome plc, most recently as Vice President of Research. Prior to working at Affymax, he held scientific positions at Protein Design Labs, Inc. and Anergen, Inc. As a staff scientist at Protein Design Labs, Inc. (now PDL BioPharma, Inc., or PDL), he co-invented the technology underlying the creation of fully humanized antibody therapeutics and applied that to PDL’s first product, Zenapax (daclizumab). Dr. Selick serves as Lead Director of PDL, a public company, and serves as Chairman of the board of directors of Catalyst Biosciences, a privately held drug discovery and development company. Dr. Selick received his B.A. in Biophysics and Ph.D. in Biology from the University of Pennsylvania and was a Damon Runyon-Walter Winchell Cancer Fund Fellow and an American Cancer Society Senior Fellow at the University of California, San Francisco.

Bryan Giraudo

Bryan Giraudo

Independent Director, Chief Financial Officer, Gossamer Bio Bio Bio
X
Bryan Giraudo

Bryan Giraudo

Independent Director,
Chief Financial Officer, Gossamer Bio

Mr. Giraudo has recently joined us as a member of our board of directors. He has served as Chief Financial Officer of Gossamer Bio since May 2018. From August 2009 to May 2018, Mr. Giraudo served as Senior Managing Director at Leerink Partners, where he was responsible for Leerink’s Western North America and Asia life sciences investment banking practice. While at Leerink, he executed more than 150 initial public offerings, follow-on, convertible and structured debt and equity transactions, as well as product and company buy-side, sell-side and corporate collaboration strategic advisory assignments for biotechnology and pharmaceutical clients. From July 1997 to July 2009, Mr. Giraudo was a Managing Director in Merrill Lynch’s Global Healthcare Investment Banking Group. Mr. Giraudo received his B.A. from Georgetown University.

Sarah Noonberg, M.D., Ph.D.

Sarah Noonberg, M.D., Ph.D.

Independent Director, Chief Medical Officer, Maze Therapeutics Bio Bio
X
Sarah Noonberg, M.D., Ph.D.

Sarah Noonberg, M.D., Ph.D.

Independent Director,
Chief Medical Officer, Maze Therapeutics

Dr. Noonberg has served as a member of our board of directors since December 2017 and is currently Chief Medical Officer at Maze Therapeutics. Prior to joining Maze she was Chief Medical Officer at Nohla Therapeutics leading development of a universal cell therapy for hematologic malignancies. Other executive leadership roles have included Chief Medical Officer of Prothena Biosciences where she led programs in hematology and immunotherapy, Head of Global Clinical Development at BioMarin where she advanced a broad portfolio of development programs for rare genetically-defined diseases, and Senior Vice President at Medivation where she led translational and early development activities as well as late stage development of enzalutamide (XTANDI™) for advanced prostate cancer. Dr. Noonberg also serves on the Board of Directors at Neoluekin Therapeutics. Dr. Noonberg earned her M.D. at the University of California, San Francisco and her Ph.D. in Bioengineering at the University of California, Berkeley. Dr. Noonberg is a board-certified internist and completed her residency at Johns Hopkins Hospital.

Sarah O’Dowd

Sarah O’Dowd

Independent Director Bio Bio
X
Sarah O’Dowd

Sarah O’Dowd

Independent Director

Ms. O’Dowd has recently joined us in August 2020 as an independent member of our board of directors. From September 2008 to March 2020 she served as Senior Vice President, Chief Legal Officer and Secretary of Lam Research Corporation, an S&P 500 company. She also served as its VP of Global Human Resources from March 2009 to May 2012. From February 2007 to August 2008 she served as Vice President and General Counsel of FibroGen, Inc. She has advised multiple public and private life science companies on M&A, strategic transactions and governance, including ALZA Corporation, Jazz Pharmaceuticals, Corcept Therapeutics, Adeza BioMedical, and Threshold Pharmaceuticals. She also serves on the board of directors of Ichor Corporation. She received a J.D. and an M.A. in Communications from Stanford University and an A.B. in Mathematics from Immaculata College.

Dinesh V. Patel, Ph.D.

Dinesh V. Patel, Ph.D.

Director, President & CEO,
Protagonist Therapeutics
Bio Bio
X
Dinesh V. Patel, Ph.D.

Dinesh V. Patel, Ph.D.

Director,
President & CEO, Protagonist Therapeutics

Dr. Patel has served as a member of the board of directors and as the President and Chief Executive Officer of Protagonist since December 2008. He has 33 years of executive, entrepreneurial, and scientific experience that span the pharmaceutical, biotechnology and biopharmaceutical industries. Prior to joining Protagonist Therapeutics, Dr. Patel served from 2006 to 2008 as the President and Chief Executive Officer of Arête Therapeutics, a privately held company focused on novel drugs for metabolic syndrome. Previously, he was the Chief Executive Officer and Co-founder of Miikana Therapeutics, an oncology based company, from 2003 until acquired by Entremed (later renamed CASI Pharmaceuticals) in 2005. Prior to Miikana, Dr. Patel held positions of increasing responsibility at Versicor (later renamed Vicuron) from 1996 to 2003, most recently as Senior Vice President of Drug Discovery and Licensing. Vicuron research and development efforts led to two marketed drugs, anidulafungin (Eraxis®), and Dalbavancin (Dalvance®), and the Company was acquired by Pfizer in 2005 in a $1.9 billion cash transaction. From 1993 to 1996, Dr. Patel was a director of chemistry at the combinatorial chemistry company Affymax. Dr. Patel was a medicinal chemist at Bristol-Myers Squibb from 1985 to 1993. Dr. Patel received his Ph.D. in Chemistry from Rutgers University, New Jersey and his B.S. in Industrial Chemistry from S. P. University, Vallabh Vidyanagar, India.

William D. Waddill

William D. Waddill

Independent Director Bio Bio
X
William D. Waddill

William D. Waddill

Independent Director

Mr. Waddill has served as a member of our board of directors since July 2016. From April 2014 to December 2016, Mr. Waddill served as Senior Vice President, Chief Financial Officer, Treasurer and Secretary of Calithera Biosciences, Inc. From October 2007 to March 2014, Mr. Waddill served as Senior Vice President and Chief Financial Officer at OncoMed Pharmaceuticals, Inc., a biopharmaceutical company. From October 2006 to September 2007, Mr. Waddill served as the Senior Vice President, Chief Financial Officer of Ilypsa, Inc., a biotechnology company that was acquired in 2007 by Amgen, Inc. From February 2000 to September 2006, Mr. Waddill served as a Principal at Square One Finance, a financial consulting business. From December 1996 to February 2000, Mr. Waddill served as Senior Director of Finance and Administration at Exelixis, Inc., a biotechnology company. Mr. Waddill received a B.S. in Accounting from the University of Illinois, Chicago, and a certification as a public accountant, which is currently inactive, after working at Pricewaterhouse Coopers LLP and Deloitte LLP.

Lewis T. “Rusty” Williams, M.D., Ph.D.

Lewis T. “Rusty” Williams, M.D., Ph.D.

Director, Co-Founder, Chairman and CEO of Walking Fish Therapeutics Bio Bio
X
Lewis T. “Rusty” Williams, M.D., Ph.D.

Lewis T. “Rusty” Williams, M.D., Ph.D.

Director,
Co-Founder, Chairman and CEO of Walking Fish Therapeutics

Dr. Williams, Co-Founder, Chairman and CEO of Walking Fish Therapeutics and a Venture Partner at Quan Capital, has served as a member of our board of directors since June 2017. He founded Five Prime Therapeutics, Inc. in December 2001 and served as Executive Chairman of the Board until 2012 and as President and Chief Executive Officer from August 2011 to December 2017. He is currently a member of the Five Prime Board of Directors. Previously, Dr. Williams spent seven years at Chiron Corporation, now Novartis Vaccines and Diagnostics, Inc., most recently as Chief Scientific Officer. He also served on Chiron’s board of directors from 1999 to 2001. Prior to joining Chiron, Dr. Williams was a professor of medicine at the University of California, San Francisco and served as director of the University’s Cardiovascular Research Institution and Daiichi Research Center. Dr. Williams also has served on the faculties of Harvard Medical School and Massachusetts General Hospital and co-founded COR Therapeutics, Inc., a biotechnology company focused on cardiovascular disease. He is a member of the National Academy of Sciences and a fellow of the American Academy of Arts and Sciences. Dr. Williams was previously a member of the boards of directors of COR Therapeutics, Inc. and Beckman Coulter, Inc., each of which was a public company. Dr. Williams received a B.S. from Rice University and an M.D. and a Ph.D. from Duke University.

Corporate Headquarters Protagonist Therapeutics Inc.

7707 Gateway Boulevard, Suite 140 Newark, CA 94560-1160 USA

Ph: +1 510 474 0170 info@ptgx-inc.com

Protagonist Pty Ltd

306 Carmody Road St Lucia, Brisbane Qld 4072 Australia

Ph: +61 (7) 3346 2975 Fax: +61 (7) 3346 2379

(Image courtesy of Graham Meltzer)